Home | Welcome to Contract Pharma   
Last Updated Friday, May 29 2015


Isis Earns $1M GSK Milestone

Published June 24, 2014
Related Searches: Phase II
Isis Pharmaceuticals, Inc. has earned a $1 million milestone payment from GlaxoSmithKline for the advancement of the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). GSK is developing ISIS-TTRRx as a treatment for transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. 
To date, Isis has earned $26 million in upfront and milestone payments for advancing ISIS-TTRRx. If GSK exercises its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and royalties.
"We are very pleased with the progress we are making with ISIS-TTRRx.  In addition to being on schedule for enrollment, we have initiated an open-label extension study of ISIS-TTRRx, which is being offered to those patients with FAP who have completed dosing in the Phase II/III study of ISIS-TTRRx," said B. Lynne Parshall, chief operating officer at Isis.  

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On